Aimmune Therapeutics

117 articles with Aimmune Therapeutics

• Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress

  5/24/2019

  Full Results from Phase 3 ARTEMIS Study Will Be Featured

• New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut

  5/21/2019

  Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results of a new study of U.S. adolescents with peanut allergy that found more than half required a visit to the emergency room or urgent care and one-third required hospitalization as a result of peanut exposure in the past 12 month

• Aimmune to Present at RBC Capital Markets Global Healthcare Conference

  5/16/2019

  Chief Financial Officer, Eric Bjerkholt, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 2019, at 2:35 p.m. E.T. in New York City.

• Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy

  5/16/2019

  Company Enters into Commercial Supply Agreement for AR101

• Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights

  5/8/2019

  Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter ended March 31, 2019

• Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

  5/1/2019

  Aimmune Therapeutics, Inc. announced that it will host a conference call on Wednesday, May 8, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2019, and recent operational highlights.

• 

  Potential Pricing of Peanut Allergy Treatments Too High, Report Says

  4/10/2019

  With the ever-rising concerns over the costs of various prescription medications, a report from consumer pharmaceutical watchdog group Institute for Clinical and Economic Review released a report questioning the potential pricing of two yet-to-be-approved peanut allergy treatments.

• Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference

  4/3/2019

  Aimmune Therapeutics, Inc. announced that Jayson Dallas, M.D., President and Chief Executive Officer, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019, at 8:00 a.m. Eastern Time in New York City.

• European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint

  3/25/2019

  Aimmune Therapeutics, Inc. announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS, met its primary efficacy endpoint.

• 

  Biotechs by the Bay Boom With Business Bounty

  3/25/2019

  When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.
• 

  Aimmune's Peanut Allergy Product Hits Primary Endpoints in European Phase III Trial

  3/25/2019

  Brisbane, Calif.-based Aimmune Therapeutics announced that its Phase III European clinical trial of AR101 for treatment of peanut allergy met its primary efficacy endpoint.
• 

  7 Drugs Expected to Be Blockbusters by 2023

  3/20/2019

  A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.

• U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy

  3/18/2019

  Aimmune Therapeutics, Inc. announced that the Biologics License Application (BLA) for AR101 has been accepted for review by the U.S. Food and Drug Administration (FDA).

• Aimmune Therapeutics to Participate in Three Investor Conferences in March

  3/5/2019

  Aimmune Therapeutics, Inc. announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in March

• Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights

  2/28/2019

  Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, announced financial results for the fourth quarter and full year 2018.

• 

  Vantage Report 2018: Research Dragged, but Biotech IPOs and Startups Soared

  2/28/2019

  Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.

• Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment

  2/25/2019

  AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE

• Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights

  2/21/2019

  Aimmune Therapeutics, Inc. announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.

• Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting

  2/4/2019

  Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy, and peanut allergy at the 2019 American Academy of Asthma, Allergy and Immunology (AAAAI) Annual Meeting, taking place February 22–25 in San Francisco.

• Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer

  1/18/2019

  Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning